Trial
NCT05269667
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
Chugai Pharmaceutical Co.
Condition
Neuromyelitis Optica Spectrum Disorder
Intervention
Satralizumab 120 mg
Why stopped
Study has proved infeasible to recruit in sufficient numbers. There are insufficient eligible patients presenting to sites.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-22